Vaxil Announces Positive Results on CorVax™ in vivo Study

NESS-ZIONA, Israel I September 08, 2020 I VAXIL BIO LTD. (“Vaxil” or the “Company”) (TSX VENTURE: VXL), an innovative immunotherapy biotech company specializing in cancer and infectious diseases, is pleased to announce that it has achieved positive results for the in vivo (animal) immunogenicity study which commenced on July 14, 2020.

The experiments, performed at the Medical Research, Infrastructure, and Health Services Fund of the Tel Aviv Sourasky Medical Center in Israel (the “Tel Aviv Sourasky Medical Centre”) were designed to evaluate, in vivo, the immune response to CorVax. The results successfully demonstrated both cellular and humoral responses to multiple signal peptides as well as to CorVax, composed of multiple signal peptides. These results further confirm the potential in the design of Vaxil’s COVID-19 vaccine candidate and provide additional evidence that it generates the anticipated immune response. A total of three injections were inoculated in two mouse strains to better simulate the human immune environment for which CorVaxwas specifically designed. Both mouse strains exhibited a humoral response, developing antibodies as early as 10 days after last injection. Both strains also displayed activated T cells against the signal peptides.

We are delighted with these results, which indicate that further work is warranted to solidify the evidence behind the success of this study,” said Dr. David Hagin, Director of the Allergy and Clinical Immunology Unit at the Tel Aviv Medical Sourasky Center, and continued “from the outset, I was intrigued by Vaxil’s novel solution to a potential COVID-19 vaccine. We are seeing hundreds of patients at our hospital, daily, and therefore, to be involved in developing a potential solution to a global pandemic is particularly fulfilling.”

We are very pleased with the outcome of this study, and will now weigh next steps to continue to produce more data, eventually to achieve approval to launch a clinical trial,” said David Goren, Vaxil’s Chairman and Chief Executive Officer, and continued, “our collaboration with Dr. Hagin and his team at the Tel Aviv Sourasky Medical Centre is extremely effective and I thank Dr. Hagin and his team for their outstanding commitment and professionalism.

The study was performed by a third-party world leading tertiary medical center according to Israeli regulations and the results are expected to be published in the future.

We expect to provide a further update within the next eight weeks.


Vaxil is an Israeli immunotherapy biotech company focused on its novel approach to targeting prominent cancer markers and infectious diseases. Its lead product ImMucin™ successfully completed a Phase 1/2 clinical trial in multiple myeloma for which it received orphan drug status from the FDA and EMA. The company aims to continue to develop ImMucin™, a COVID-19 and a tuberculosis vaccine / treatment that has demonstrated promising preliminary results with further preclinical evaluation planned. Additional indications and mAb candidates are under evaluation as immuno-oncology and infectious disease treatments alone and in combination with other treatments.

Vaxil exploits the unique properties of signal peptide domains on crucial proteins to develop targeted therapies against cancer targets and infectious disease pathogens. These signal peptide domains are identified by VaxHit™, Vaxil’s proprietary bioinformatic approach. These signal pepdies induce a robust T- and B-cell response across wide and varied HLA subtypes, while acting as true, universal neoantigens. The peptide platform targets these cells by “educating” or specifically activating the immune system to recognize and attack the affected cells. In addition, Vaxil’s mAb platform directly recognizes the target protein expressed on malignant cells and recruits other elements of the immune system to lyse those cells.

The Company is not making any express or implied claims that it has completed developing or will be successful in developing a COVID-19 (or SARS-CoV-2) vaccine at this time.

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.


La Merie Biologics

FREE Weekly News Bulletin

Sign Up

2022 Sales ofAntibodies & Proteins

New Product Alert

For La Merie Publishing

Sign Up